Carvedilol Diminishes Cardiac Remodeling Induced by High-Fructose/High-Fat Diet in Mice via Enhancing Cardiac β-Arrestin2 Signaling.

abstract：:Cardiovascular diseases are one of the most common causes of death in humans and are responsible for billions of dollars in health care expenditures. As the molecular basis of cardiac diseases continues to be explored, there remains the hope for identification of more effective therapeutics. MicroRNAs (miRNAs) are rec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Calway T,Kim GH

更新日期：2015-03-01 00:00:00

abstract：BACKGROUND:Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. DESIGN:The present study was performed to evaluate whether combination therapy of cl...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Niu Q,Wang Z,Zhang Y,Wang J,Zhang P,Wang C,Yin X,Hou Y

更新日期：2017-03-01 00:00:00

abstract：:The antiarrhythmic potential of postconditioning in in vivo models remains poorly defined. We compared the effects of pre- and postconditioning on ventricular arrhythmogenesis against controls with and without reperfusion. Wistar rats (n = 40, 269 ± 3 g) subjected to ischemia (30 minutes)--reperfusion (24 hours) were ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kolettis TM,Vilaeti AD,Tsalikakis DG,Zoga A,Valenti M,Tzallas AT,Papalois A,Iliodromitis EK

更新日期：2013-07-01 00:00:00

abstract：:Cardio-Oncology has blossomed as a new field in cardiovascular medicine, in large part due to new therapies, which may have cardiovascular sequelae. Despite this, anthracyclines still serve as cornerstone therapy for most pediatric cancers, several solid tumors and hematological malignancies. Cardiotoxicity is the mai...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Screever EM,Meijers WC,Moslehi JJ

更新日期：2021-03-01 00:00:00

abstract：:Myocardial ischemic injury and cardioprotection are characterized by a cascade of molecular changes, which includes gene expression, protein expression, protein localization, interactions, and posttranslational modifications (PTMs). A systems biology approach allows the study of these genes and proteins on a large sca...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Lotz C,Liem D,Ping P

更新日期：2011-09-01 00:00:00

abstract：:Nonvalvular atrial fibrillation (AF) confers an increased risk of thromboembolism, with a 5-fold higher risk of ischemic stroke. Oral anticoagulation (OAC) has shown to be highly effective in preventing stroke and mortality compared to placebo and is also used in patients without AF for both treatment and prophylaxis ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gallego P,Roldán V,Lip GY

更新日期：2014-01-01 00:00:00

abstract：:BACKGROUND: The electrophysiologic mechanisms of the persistence of atrial fibrillation (AF) after its initiation are not well understood. Therefore, the electrophysiologic characteristics of the right atrium were evaluated in an acute, pacing-induced model of AF in the pig in order to identify parameters associated w...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Rahme MM,Cotter B,Leistad E,Subudhayangkul S,Wadhwa M,Ungab G,Feld GK

更新日期：1999-04-01 00:00:00

abstract：:The gap junction modifier Rotigaptide (ZP123), which promotes cellular coupling, was hypothesized to decrease defibrillation thresholds during prolonged ventricular fibrillation (VF). Thirty-two New Zealand white rabbits were randomized to receive saline (control, n = 16) or Rotigaptide (n = 16). Following 4 min of un...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Zhong JQ,Laurent G,So PP,Hu X,Hennan JK,Dorian P

更新日期：2007-03-01 00:00:00

abstract：:The results of numerous long-term, randomized trials show that statins significantly decrease the risks of myocardial infarction, stroke, and vascular death as well as total mortality. The benefits of statins on cardiovascular disease in patients who are not experiencing acute coronary syndromes generally become appar...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Novela C,Hennekens CH

更新日期：2004-03-01 00:00:00

abstract：INTRODUCTION:Angiotensin converting enzyme inhibitors (ACEIs) are widely prescribed medications. A recent British study reported a 14% increased risk of lung cancer with ACEI versus angiotensin receptor blocker (ARB) prescriptions, and risk increased with longer use. We sought to validate this observation. METHODS:We ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Anderson JL,Knowlton KU,Muhlestein JB,Bair TL,Le VT,Horne BD

更新日期：2021-01-29 00:00:00

abstract：OBJECTIVE:Acute lung injury is a common complication after cardiopulmonary bypass (CPB). Oxidative damage greatly impacts CPB-induced lung ischemic pathogenesis and may represent a target for treatment. We aimed to investigate whether curcumin upregulates heme oxygenase 1 (HO-1) expression and ameliorates lung injury i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Liu K,Chen HL,Huang H,Jing H,Dong GH,Wu HW,You QS

更新日期：2012-12-01 00:00:00

abstract：:α-Lipoic acid (LA) has been shown to offer protection against ischemia-reperfusion injury (IRI) in multiple organ systems. N-[(R)-1,2-dithiolane-3-pentanoyl]-L-glutamyl-L-alanine (CMX-2043), a novel analogue of LA, was studied as part of a preclinical development program intended to identify safe and efficacious drug ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Baguisi A,Casale RA,Kates SA,Lader AS,Stewart K,Beeuwkes R 3rd

更新日期：2016-11-01 00:00:00

abstract：:Antiplatelet therapy is indicated for the treatment of ischemic stroke or transient ischemic attack (TIA). Aspirin reduces subsequent occlusive vascular events, including recurrent stroke, by about 25%. In such patients, clopidogrel has been evaluated in an effort to further reduce risk. In the Management of Atherothr...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Gorelick P,Sechenova O,Hennekens CH

更新日期：2006-12-01 00:00:00

abstract：BACKGROUND:Patients with coronary artery disease (CAD) should be treated with statins to attain very low cholesterol levels, in order to reduce cardiovascular adverse events. More than 70% of these patients do not reach the appropriate cholesterol goal despite moderate statin doses. However, it is not known whether the...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Pesaro AE,Serrano CV Jr,Katz M,Marti L,Fernandes JL,Parra PR,Campos AH

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Intimal hyperplasia following percutaneous interventional vascular procedures is a major cause of restenosis. Although heparin inhibits intimal hyperplasia, it has not proven clinically useful in part due to an inadequate duration of intramural drug residence. This study was designed to evaluate the efficacy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sasseen BM,Gray BD,Gal D,Lorinc R,Carpenter DC,Klugherz BD,Wilensky RL

更新日期：2001-10-01 00:00:00

abstract：:Qiliqiangxin (QL), a traditional Chinese medicine, has been shown to be beneficial for chronic heart failure. However, whether QL can also improve endothelial cell function in diabetic rats remains unknown. Here, we investigated the effect of QL treatment on endothelial dysfunction by comparing the effect of QL to tha...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Chen F,Wu JL,Fu GS,Mou Y,Hu SJ

更新日期：2015-03-01 00:00:00

abstract：:The primary effect of ischemia is reduced aerobic adenosine triphosphate (ATP) formation in mitochondria. This triggers accelerated glycolysis and reduced cell pH, Ca(2+) accumulation, K(+) efflux, adenosine formation, and the clinical signs of ischemia: chest pain and a shift in the ST segment. Traditional therapies ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Stanley WC

更新日期：2004-09-01 00:00:00

abstract：BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a speci...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Zhou M,Ma C,Liu W,Liu H,Wang N,Kang Q,Li P

更新日期：2015-09-01 00:00:00

abstract：:Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wang D,Liu T,Shi S,Li R,Shan Y,Huang Y,Hu D,Huang C

更新日期：2016-11-01 00:00:00

abstract：PURPOSE:It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tosaka S,Tosaka R,Matsumoto S,Maekawa T,Cho S,Sumikawa K

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:We investigated whether the cardioprotective, volatile gas anesthetic agent, isoflurane, could improve survival and organ function from hemorrhagic shock in an experimental rat model, compared to standard nonvolatile anesthetic agent ketamine/xylazine. METHODS:Sprague Dawley rats (both genders) were randomi...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Dai W,Shi J,Carreno J,Kloner RA

更新日期：2020-07-01 00:00:00

abstract：:A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh N

更新日期：2002-04-01 00:00:00

abstract：BACKGROUND:Omapatrilat has potent enzymatic inhibitory effects on the angiotensin-converting enzyme and neutral endopeptidase. The prolonged effects of this inhibition on systemic and regional hemodynamics, cardiovascular mass, and hydroxyproline concentration in spontaneously hypertensive rats were studied. The contri...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Varagic J,Susic D,Slama M,Frohlich ED

更新日期：2003-06-01 00:00:00

abstract：:Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomit...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ilebekk A,Eriksen M,Sevre K,Aspelin T,Björkman JA,Lyberg T,Nordlander M

更新日期：2006-09-01 00:00:00

abstract：INTRODUCTION:Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF). Our purpose was to evaluate the comparative effect on urine output (UO) and renal function between these regimens. METHODS:A retrospective study of hospitali...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ng TM,Konopka E,Hyderi AF,Hshieh S,Tsuji Y,Kim BJ,Han SY,Phan DH,Jeng AI,Lou M,Elkayam U

更新日期：2013-07-01 00:00:00

abstract：:Effects of therapy with the potassium-channel opener and vasodilator nicorandil were studied in reperfused infarction of hypertrophied hearts by using magnetic resonance imaging (MRI), hemodynamic measurements, and histochemical staining. Aortic banding was performed on 22 Sprague-Dawley rats to induce left ventricula...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Schalla S,Higgins CB,Chujo M,Saeed M

更新日期：2004-09-01 00:00:00

abstract：:We evaluated whether carotenoid astaxanthin (ASX) could prevent oxidative and atherosclerotic damage in rabbits. Rabbits received regular chow (control) or an atherogenic diet (1% cholesterol) alone or supplemented with 50, 100, and 500 mg% ASX for 60 days (n = 5-9 per group). The atherogenic diet increased the serum ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Augusti PR,Conterato GM,Somacal S,Sobieski R,Quatrin A,Maurer L,Rocha MP,Denardin IT,Emanuelli T

更新日期：2009-12-01 00:00:00

abstract：:BACKGROUND: The tendency for the electrophysiologic effect of class III antiarrhythmic agents (action potential prolongation) to be diminished at faster heart rates represents a major drawback of this class of drug and is usually referred to as "reverse use dependence." A novel class III agent, MS-551, has recently be...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Nakaya Y,Martin DK,Campbell TJ

更新日期：1997-01-01 00:00:00

abstract：:Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Narechania S,Torbic H,Tonelli AR

更新日期：2020-03-01 00:00:00

abstract：:Dronedarone is a new antiarrhythmic drug for patients with nonpermanent atrial fibrillation (AF). A relatively consistent finding in all trials studying dronedarone was a moderate but significant elevation of serum creatinine. Since dronedarone competes for the same organic cation transporter in the distal renal tubul...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Duncker D,Oswald H,Gardiwal A,Lüsebrink U,König T,Schreyer H,Klein G

更新日期：2013-03-01 00:00:00